Supriya Lifescience Ltd (SUPRIYA) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Supriya Lifescience reported strong Q3 FY25 results, with revenue up 33% YoY to INR186 crores driven by robust demand.
- EBITDA margin reached 35.5% and PAT margin 25%, reflecting operational efficiency and focus on high-margin niche products.
- Exports contributed 85% of revenue, reflecting growth in regulated markets, particularly LATAM (21% of revenue).
- Module E block at Lote Parshuram facility commissioned, adding 335 KLPD to capacity, bringing total capacity to over 1,000 KLPD.
- Company maintains its revenue growth guidance of 20% with strong margins and aims to double revenue to INR1,000 crores by FY27.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.